VERTO MD is a privately held service provider specializing in:
- Clinical trials phases I-IV, focused on First in Human (FiH), Dose-Finding, Proof of Concept (PoC) studies
- Investigational New Drug Applications (IND) & Clinical Trial Applications (CTA), New Drug Applications (NDA), Marketing Authorization Applications (MAA), Accelerated Approvals (AA) – submissions to FDA/EMA/PMDA
- Global markets: US, EU, and Canada, Middle East, Turkey and Africa (META), Japan, South Asia & Australia (APAC), Russia & CIS, Latin America (LATAM), China
- Therapeutic Areas: rare diseases, oncology, immuno-oncology, infectious diseases, neuromuscular and metabolic disorders. Small and macromolecules, monoclonal antibodies and drug conjugates, targeted therapies, cell therapies, stem cells and GMO/GMM based technologies, personalized medicine, translational medicine, biomarkers.
The main VERTO MD therapeutic areas include immunology and oncology, having experience in indications including but not limited to niche or orphan indications like CD37+, CD30+, CD19+, CD20+, ILRAP-1 expressing malignancies, FcRn, PD-1/PDL-1 targeting, Notch signaling, HDAC inhibitors, proteasome inhibitors between others.
